What did @docgracepharmacy actually say?
Honestly? Not much, at least verbally. The transcript is a motivational phrase about process over results: "Focused on the process, not the prey, not the likes, not the wins, not the race. Don't stress what I can't control, I train." The actual content claims live in the hashtags and caption, not the spoken words. The caption reads "Reta work" with heart emojis, and the hashtags include #retatrutide, #ghkcu, and #peptideliptreatment. That framing implies the creator is using or administering retatrutide and GHK-Cu, and that something is working for them. In regulatory terms, that kind of implied endorsement carries the same weight as a direct claim. The video has 12.6K views, so the implication lands with real reach.
This is a pattern worth naming: when creators let hashtags and captions do the claiming while the audio stays vague, fact-checkers still have to assess what the audience is actually being told. Here, the audience is being told retatrutide works and that GHK-Cu is part of a legitimate treatment protocol.
Does the science back this up?
For retatrutide, the early data is genuinely interesting but nowhere near settled. For GHK-Cu, the picture is more complicated, and the "peptide lip treatment" framing deserves scrutiny.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. A Phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine) showed mean weight loss of up to 24.2% over 48 weeks in adults with obesity, which is a larger reduction than seen with tirzepatide in comparable timeframes. That is a real result from a real trial. However, retatrutide is not FDA-approved. It is in Phase 3 trials as of 2024. Compounded versions circulating in telehealth markets are not the same molecule tested in those trials, and no one should pretend otherwise.
GHK-Cu (copper peptide) has a different evidence base. In vitro studies, including work by Pickart and Margolina (2018, Frontiers in Aging Neuroscience), show it promotes wound healing, collagen synthesis, and has antioxidant properties in cell culture. Human clinical trial data is thin. A small study by Leyden et al. (2018) looked at topical application for skin, showing modest improvements. Systemic or injected GHK-Cu in humans lacks robust safety and efficacy data.
What did they get wrong (or right)?
Credit where it is due: if the creator is simply documenting personal use of retatrutide during an active investigational period, that is not automatically irresponsible. The "focused on process" framing at least avoids wild outcome promises. They did not claim retatrutide cures obesity or that GHK-Cu reverses aging. That matters.
What they got wrong, or at least sidestepped, is context. Combining retatrutide with GHK-Cu under the label "peptide lip treatment" suggests a protocol without acknowledging that neither compound is FDA-approved for the implied uses. The hashtag #healthboost applied to an unapproved investigational drug is the kind of casual framing that erodes informed consent in a public audience. Retatrutide carries real side effect risks including nausea, vomiting, tachycardia, and potential thyroid concerns flagged in the Jastreboff trial. None of that appears here.
The implied message that this stack is routine or proven is where the video does its quiet damage. Twelve thousand people saw "Reta work" and heart emojis. That is not neutral communication.
What should you actually know?
Retatrutide is one of the more promising weight loss compounds in development, but promising and approved are different categories. The Phase 2 data from Jastreboff et al. (2023) generated real scientific interest, and Phase 3 results are anticipated. Until then, any retatrutide you can buy through a compounding pharmacy or peptide supplier is not the molecule that produced those trial results. Purity, dosing accuracy, and sterility are not guaranteed outside of clinical trial supply chains.
GHK-Cu applied topically has some legitimate cosmetic dermatology support. Injected or systemically administered GHK-Cu in humans is a different question with much less data. Calling it a "lip treatment" alongside an investigational GLP-1 agonist in the same hashtag cluster creates a misleading impression of an established protocol.
If you are considering either compound, that conversation belongs with a licensed provider who can access your full health history, not a TikTok hashtag. FormBlends operates under prescriber oversight for exactly this reason.